Navigation Links
X-BODY BioSciences to Present Novel Methods of Selecting for Antibodies Against Targets on Live Cells at CHI's Protein Engineering Summit
Date:4/27/2012

WALTHAM, Mass., April 27, 2012 /PRNewswire/ -- X-BODY BioSciences, Inc., a developer of monoclonal antibody therapeutics, today announced it will present novel methods of selecting for antibodies against targets on the surface of live cells at CHI's Protein Engineering Summit (PEGS) and the associated Biologics Partnering Forum being held April 28th through May 4th in Boston, Massachusetts. 

Richard Wagner, Ph.D., Co-Founder and Executive Chairman of X-BODY, will present a talk entitled, "Predicting Antibody Binding Properties by Interrogation of Fully Human Libraries with Deep Sequencing" on Saturday, April 28th at 4:15 PM.

Yan Chen, M.D./Ph.D., Senior VP of Research and Development at X-BODY, will present a talk entitled, "Generation and Optimization of Fully Human VH Domain Antibodies and IgG Using dsDNA Display with Deep Sequence Hit Analysis" on Tuesday, May 1st at 3:05 PM. 

A poster entitled, "Selection of Fully Human Antibodies Targeting HER2 Expressed on Live Cells with dsDNA Display and Massively Parallel Deep Sequencing Analysis" will also be presented by X-BODY at the conference on April 30th-May 1st.

X-BODY recently expanded its internal capabilities by hiring an expert team in performing live cell screening, deep sequence bioinformatics, and engineering.  X-BODY's novel proprietary system allows for performing antibody selections on live cells while simultaneously analyzing the cell binding characteristics of thousands of antibody hits.  X-BODY is now applying this live cell selection platform in four research alliances forged since January 2011 which are funded by X-BODY's research partners:  Alvos Therapeutics,  BioMed Valley Discoveries (established by the Stowers Institute for Medical Research), Tanabe Research Laboratories U.S.A., Inc. (an independent subsidiary of Mitsubishi Tanabe Pharma Corporation) and an undisclosed mid-cap biotechnology company.  X-BODY BioSciences has also applied live cell antibody selection technology to its internal programs in Oncology and Ophthalmology. 

About X-BODY BioSciences, Inc.
X-BODY BioSciences was founded in 2008 by Richard Wagner, Ph.D., Gordon Binder, and Brant Binder, MBA. X-BODY's platform enables rapid discovery of human antibody therapeutics by interrogation of extraordinarily diverse fully human libraries. X-BODY's versatile selection system employs next-generation sequencing to analyze thousands of hits in order to rapidly obtain high quality leads.   The modular leads generated by X-BODY's platform can be incorporated into VH domain, scFv, IgG and bispecific antibody formats.    X-BODY's lead molecule, XB-2202, is a potent inhibitor of PDGF Receptor Beta and has potential applications in treating Age-Related Macular Degeneration (AMD) and solid tumors.    

WEB: www.x-bodybiosciences.com


'/>"/>
SOURCE X-BODY BioSciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. X-BODY BioSciences Awarded Grant for Therapeutic Discovery Project Targeting Metastatic Tumor Stem Cells
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... ... a company focused on discovery and development of precision treatments for neurodegenerative ... developing for Alzheimer’s disease (AD) inhibited the direct neurotoxic effect of prion-like ...
(Date:12/5/2016)... Dec. 5, 2016 Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced that ... treatment of Alzheimer,s disease will be presented at the ... Friday, December 9, 2016 in San Diego ... of both simple and complex measures of activities of ...
(Date:12/5/2016)... Research and Markets has announced the addition of Jain ... to their offering. ... , This report describes different ... as proteomics and metabolomics. Molecular diagnostics technologies are used for the ... Currently the most important applications of biomarkers are in ...
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... MA to soon resume cervical and lumbar disc production, company President, Jake Lubinski ... surgeons who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/24/2016)... Nov. 23, 2016 Cercacor today introduced Ember ... their trainers non-invasively measure hemoglobin, Oxygen Content, ... and Respiration Rate in approximately 30 seconds. Smaller than ... and immediate access to key data about their bodies ... training regimen. Hemoglobin carries oxygen to ...
(Date:11/17/2016)... 2016 Global Market Watch: Primarily supported ... Population-Based Banks and Academics) market is to witness a value ... shows the highest Compounded Annual Growth Rate (CAGR) of 10.75% ... the analysis period 2014-2020. North America ... by Europe at 9.56% respectively. ...
Breaking Biology News(10 mins):